Article

COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study

2022-07-18

Abstract excerpt

<h4>Background</h4> Vaccination has been effective in preventing COVID-19 infections and related mortality. However, waning immunity after the two-dose vaccination prompted health authorities to recommend a third dose of COVID-19 vaccine to boost immunity. The aim of our study was to assess willingness to receive a third (booster) dose among patients with IBD. <h4>Methods</h4> A cross-sectional study was performed...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4fb31077-89d1-50a0-adc7-ca1f16ee6d33
DOI: 10.1101/2022.07.18.22277757

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional StudyDOI 10.1101/2022.07.18.22277757Read

COVID-19 Vaccine Hesitancy Among Patients with Inflammatory Bowel Disease on Biologic Therapies; A cross-sectional studySemantic proximity Read

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialSemantic proximity Read

COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine DoseSemantic proximity Read

Attitudes towards Vaccinations in a National Italian Cohort of Patients with Inflammatory Bowel DiseaseSemantic proximity Read

Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)Semantic proximity Read

Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patientsSemantic proximity Read

Immunogenicity, Safety, and Reactogenicity of a Half- Versus Full-Dose BNT162b2 (Pfizer-Biontech) Booster Following a Two-Dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac Priming Schedule in Mongolia: A Randomised, Controlled, Non-Inferiority TrialSemantic proximity Read

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity Read

Hybrid immunity improves the immune response after fourth Covid-19 vaccine dose in individuals with medical conditions predisposing to severe Covid-19Semantic proximity Read

Serological response to COVID-19 vaccination in IBD patients receiving biologicsSemantic proximity Read

COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or VedolizumabSemantic proximity Read

Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in IsraelSemantic proximity Read